Diabetes insipidus and SIADH: Pathology review

Last updated: December 08, 2021

Diabetes insipidus and SIADH: Pathology review

Watch later

Watch later

Somatostatin
Synthesis of adrenocortical hormones
Cortisol
Testosterone
Estrogen and progesterone
Phosphate, calcium and magnesium homeostasis
Parathyroid hormone
Vitamin D
Calcitonin
Congenital adrenal hyperplasia
Primary adrenal insufficiency
Waterhouse-Friderichsen syndrome
Hyperaldosteronism
Adrenal cortical carcinoma
Cushing syndrome
Conn syndrome
Thyroglossal duct cyst
Hyperthyroidism
Graves disease
Thyroid eye disease (NORD)
Toxic multinodular goiter
Thyroid storm
Hypothyroidism
Euthyroid sick syndrome
Hashimoto thyroiditis
Subacute granulomatous thyroiditis
Riedel thyroiditis
Thyroid cancer
Hyperparathyroidism
Hypoparathyroidism
Hypercalcemia
Hypocalcemia
Diabetes mellitus
Diabetic retinopathy
Diabetic nephropathy
Hyperpituitarism
Pituitary adenoma
Hyperprolactinemia
Prolactinoma
Gigantism
Acromegaly
Hypopituitarism
Pituitary apoplexy
Sheehan syndrome
Hypoprolactinemia
Constitutional growth delay
Diabetes insipidus
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Precocious puberty
Delayed puberty
Premature ovarian failure
Polycystic ovary syndrome
Androgen insensitivity syndrome
Kallmann syndrome
5-alpha-reductase deficiency
Autoimmune polyglandular syndrome type 1 (NORD)
Multiple endocrine neoplasia
Pancreatic neuroendocrine neoplasms
Zollinger-Ellison syndrome
Pheochromocytoma
Neuroblastoma
Opsoclonus myoclonus syndrome (NORD)
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Parathyroid disorders and calcium imbalance: Pathology review
Diabetes mellitus: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Pituitary tumors: Pathology review
Hypopituitarism: Pathology review
Diabetes insipidus and SIADH: Pathology review
Multiple endocrine neoplasia: Pathology review
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Bones of the cranium
Anatomy of the cranial base
Anatomy of the orbit
Anatomy of the eye
Bones of the neck
Superficial structures of the neck: Cervical plexus
Superficial structures of the neck: Anterior triangle
Deep structures of the neck: Prevertebral muscles
Anatomy of the thyroid and parathyroid glands
Anatomy of the larynx and trachea
Anatomy of the pharynx and esophagus
Introduction to the cranial nerves
Anatomy of the olfactory (CN I) and optic (CN II) nerves
Anatomy of the oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Nasal cavity and larynx histology
Anatomy and physiology of the eye
Photoreception
Optic pathways and visual fields
Anatomy and physiology of the ear
Auditory transduction and pathways
Vestibular transduction
Vestibulo-ocular reflex and nystagmus
Olfactory transduction and pathways
Taste and the tongue
Glaucoma
Retinoblastoma
Laryngomalacia
Laryngitis
Bacterial epiglottitis
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Vertigo: Pathology review
Nasal, oral and pharyngeal diseases: Pathology review
Antihistamines for allergies
Acid reducing medications
Blood histology
Sepsis
Anaphylaxis
Food allergy
Blood products and transfusion: Clinical
Bites and stings: Clinical
Hematopoietic medications
Thrombolytics
Hemophilia
The nurse and doctor and the avoidable lawsuit (Coverys)
Traumatic brain injury: Pathology review
Concussion and traumatic brain injury
Traumatic brain injury: Clinical
Brain herniation
Drug administration and dosing regimens
Sympathomimetics: Direct agonists
Muscarinic antagonists
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Laxatives and cathartics
Antidiarrheals
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Glucocorticoids
Opioid agonists, mixed agonist-antagonists and partial agonists
Nonbenzodiazepine anticonvulsants
Migraine medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Opioid antagonists
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
PDE5 inhibitors
Estrogens and antiestrogens
Progestins and antiprogestins
Androgens and antiandrogens
Aromatase inhibitors
Uterine stimulants and relaxants
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines

Transcript

Watch video only

Okay, so two people were admitted to the Endocrinology ward. One of them is 35 year old Imre, who came in with intense polyuria and polydipsia. Imre was dehydrated and presented with dry mouth, headache, dry skin and dizziness. Several tests were done and results showed increased serum osmolality and further on, a desmopressin test was done. During the test, an ADH analogue was administered and urine osmolality increased. The other person is 45 year old Sienna who came in to do some routine tests because she started taking cyclophosphamide and wanted to make sure that there are no complications. Her lab results showed hyponatremia, decreased blood osmolality, and her urine osmolality was higher than serum osmolality.

Now, both individuals are unable to maintain normal osmolality. But to understand this we need to go over a bit of physiology first. In the brain, specifically in the hypothalamus, there are osmoreceptors which can sense the osmolality of the blood, or how concentrated it is. Osmolality is the concentration of dissolved particles in the blood plasma, or the liquid portion of blood. There are a number of dissolved particles in the blood plasma, but the major ones are glucose, sodium, and blood urea nitrogen, and a normal osmolality is between 285 and 295 milliOsmoles per kilogram.

Now, during periods of dehydration there is an increase in concentration of these particles in the blood and osmolality increases. The osmoreceptors in the hypothalamus sense the change in osmolality and this triggers the sensation of thirst. The water that we drink gets absorbed and dilutes the blood, bringing the osmolality back to normal.

In addition to osmoreceptors, the hypothalamus also contains the supraoptic and paraventricular nuclei that produce antidiuretic hormone, or ADH, which is then sent to the posterior pituitary for storage. ADH is also called vasopressin because it causes smooth muscle around the blood vessels to contract, which increases resistance and raises blood pressure.

When the osmoreceptors detect high osmolality, they signal the supraoptic nucleus to send ADH into the blood which travels to the kidneys, specifically to the principal cells in the distal convoluted tubule, and collecting ducts, of the nephrons. Here ADH binds to a receptor called vasopressin receptor 2, or VR2. This causes aquaporin proteins inside the principal cells to embed into the cell membrane and open a channel that only lets water from the lumen of the nephron back into the blood. Just like drinking more water, this dilutes the blood, and returns plasma osmolality to a normal level. However, this reabsorption process also decides how much water leaves the body as urine, and how concentrated the urine is, which is one of the things that keeps a normal urine osmolality between 300 and 900 milliOsmoles per kilogram.

Now that we know all this, diabetes insipidus is when the kidneys reabsorb too little water, so the water remains in the nephrons and is lost via urine. This leads to a lot of dilute urine, or polyuria. Since there’s less water in the blood, plasma osmolality increases and that triggers thirst and polydipsia. Now, if the problem is caused by a lack of ADH, it’s called central diabetes insipidus. If it’s due to a decreased response to ADH by the kidneys, it’s called nephrogenic diabetes.

Let’s start with central diabetes insipidus, which can be caused by conditions that affect the hypothalamus, in which case it won’t be able to produce ADH, or conditions that affect the pituitary gland, in which case there’s no place to store the ADH, and in some cases, both the hypothalamus and the pituitary gland are affected. As a result, there’s insufficient ADH in the blood, and that means there is less vasoconstriction, and insufficient aquaporins in the distal convoluted tubule and collecting duct. Some causes of central diabetes insipidus include pituitary tumors, head trauma, head surgery, ischemic encephalopathy, autoimmune conditions or sometimes, the cause can be idiopathic.

Then there’s nephrogenic diabetes insipidus, which is when there’s a problem with the kidneys themselves, which makes them unresponsive to ADH. A high yield fact is that this is often due to a hereditary genetic defect of the vasopressin receptors or aquaporin proteins. Both of these lead to nephrons that are unresponsive to ADH. In addition, there are medications like lithium that can decrease the production of aquaporin proteins in the collecting duct. Sometimes, nephrogenic diabetes insipidus can be caused by hypokalemia. That’s because the aquaporins can degrade in the early phases of hypokalemia. Sometimes nephrogenic diabetes can also be secondary to hypercalcemia, through an unclear mechanism. Finally, demeclocycline, which is an ADH antagonist, can block the vasopressin receptors, leading to nephrogenic diabetes insipidus.

Now, the symptoms of both central and nephrogenic diabetes insipidus are polyuria and polydipsia and you have to remember this for your tests. A person with diabetes insipidus typically produces over 3 liters of dilute urine each day, so it can quickly lead to dehydration and hypotension. The increase in plasma osmolality can result in fatigue, nausea, poor concentration, or confusion.

The diagnosis of diabetes insipidus starts with a blood osmolality test, which would show an increased blood osmolality of above 290 milliosmoles per kilogram in both central and nephrogenic diabetes insipidus. The urine specific gravity is lower than 1006, meaning the kidneys aren’t able to properly concentrate urine. There’s also hyperosmotic volume contraction This means that there’s decreased extracellular fluid in the body, and the remaining fluid is hyperosmotic since the water is lost, but the solutes remain. Okay, the way to differentiate central and nephrogenic diabetes insipidus is to look at the ADH level; with central diabetes insipidus, there’s low ADH, while with nephrogenic diabetes insipidus, ADH is normal or high. Remember this as it’s a very high yield concept.

In addition, a water deprivation test can be done to distinguish diabetes insipidus from psychogenic polydipsia, which is when an individual drinks more water than they need, because of a variety of psychological or psychiatric causes. That’s where an individual doesn’t drink water for 2 to 3 hours, then hourly measurements of urine volume and osmolality are done. In a person with diabetes insipidus, urine osmolality will normally stay below 300 mOsm/kg despite having no fluid intake. With psychogenic polydipsia, urine osmolality increases during the test.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "undefined" Reviews in Endocrine and Metabolic Disorders (2003)
  4. "Treatment of Lithium-Induced Diabetes Insipidus with Amiloride" Pharmacotherapy (2003)
  5. "Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment" Mayo Clinic Proceedings (2010)
  6. "Syndrome of Inappropriate Antidiuretic Hormone Secretion Induced by a Single Dose of Oral Cyclophosphamide" Annals of Pharmacotherapy (2012)